The present invention is directed to braid-balls suitable for aneurysm occlusion and/or parent vessel occlusion/sacrifice (e.g., in treating neurovascular defects).
Mainstream clinical practice in endovascular treatment of intracranial aneurysms has changed little since the 1990's when vasoocclusive coil use became widespread. Certainly, improved catheters and other auxiliary devices (e.g., stents) have helped make coiling procedures safer and/or more effective. However, the art in achieving adequate and appropriate aneurysm coil packing is best accomplished by the most highly skilled physicians.
Where practicable, aneurysm exclusion by cover-type devices (e.g., as described in U.S. patent application Ser. No. 12/397,123 to the assignee hereof) may be preferred. Certain other groups are attempting to shift the paradigm away from intra-aneurysm coil packing to achieve embolization via deployment of an extra-aneurysm flow disruptor/diverter stent in the parent vessel. These densely braided devices and/or multiple braid devices layered upon one another are placed in the parent vessel across the neck of an aneurysm with the intent to alter hemodynamics so as to effect embolization.
These WALLSTENT-like devices are best suited for placement across sidewall aneurysms. Yet, terminal aneurysms (e.g., bifurcation aneurysms) are estimated by some to make-up between about 60 and 80% of all aneurysm occurrences. By most optimistic count, only about 40% of intracranial aneurysms can be treated using the referenced stent-like devices.
Numerous other devices have been conceived in effort to address terminal aneurysms. Complicated and/or impracticable deployment is common to many. Others simply serve as adjunctive to coils or liquid embolic agents. In these latter examples, procedures may become even more complicated and require even greater physician skill than a standard coiling procedure.
A simpler, yet promising solution is proposed in PCT/US 2007/0076232 to Dieck, et al. A braided/mesh conical member is described for diverting blood flow from the aneurysm neck. A base of the device is set inside the aneurysm while a flow diverter portion extends into the parent vessel to direct blood flow toward adjacent side branches and away from the aneurysm. The implant may be positioned within the aneurysm as a stand-alone device or be supported by a connected stent-like body.
U.S. Pat. Nos. 6,168,622 and 6,506,204 to Mazzochi, et al. disclose another type of braided flow disruptor set at least partly within an aneurysm. A bulbous portion is adapted to fit within the aneurysm dome and is anchored on the outside by a neck-covering flap. Given the manner in which bifurcation aneurysms often incorporate branch vessel anatomy, such a patch would often interfere with and/or “flap” free raising significant issues of potentially pathological thrombus formation within the parent vessel.
Implants of the present invention address shortcomings of each of the above-referenced devices. As such, the subject implants (as well as their associated delivery systems) offer potential to advance the state of the art in endovascular treatment of vascular malformations, including aneurysms.
The present invention is directed to wire braid ball implants for occluding blood flow at endovascular sites. Delivery systems and methods of making the balls are also described. The balls are useful for treating neurovascular defects. One use is in intracranial aneurysm embolization/occlusion and another in parent vessel occlusion (PVO) or sacrifice.
Generally speaking, the subject vascular implants are braided devices using a combination of bio-stable materials selected from Stainless Steel, Cobalt Chromium, Nitinol, Titanium, Titanium-alloys, Zirconium and Zirconium alloys, PET (or another suture material) and medical-grade adhesive. The density of the device is paramount in applications where the braid itself is intended to affect blood flow, allowing thrombosis within a volume formed by the ball to occlude a site. As such, high density braid/mesh is typically required. Namely, braid having at least about 48 ends, typically set at about 90 degrees or greater, in diameters from about 4 to about 8 mm may be employed. At larger diameters (e.g., about 6 mm to 12 mm or more), more wire ends (e.g., common multiples of 64, 72, 96, 128, 144) may be employed in forming the balls. Still higher typical wire counts may be employed. Either one of commercially available 192 and 288 carrier standard braiders may be employed. Moreover, 3-D braiding technology (such services are provided by 3Tex, Inc.) may be employed in forming the braid matrix from which the balls are formed. In addition, any combination of wire diameter, wire count, braid angle, and per-inch crossings can be used to make braid in order to configure an embolic and blood flow occlusive device deemed appropriate for a particular vascular site.
A range of wire sizes or combination of wire sizes may be employed, typically ranging from about 0.0008 to about 0.0015 inch, and up to about 0.003 inches depending on desired delivery profile (which is typically desired to be less than about 0.050 inches—at least for neurovascular indications—and more generally up to about 0.070 for peripheral PVO indications). A single braid tube may have all wires the same diameter, or may have some wires of a slightly thicker diameter to impart additional strength to the braid layer. For example, half the wires of a 96 wire tube (i.e., 48 ends) can be e.g. 0.001″ diameter and the other half of the wires can be e.g. 0.0015″ diameter. In which case, the two wire sizes would typically be interlaced uniformly in making the braid. The thicker wires impart greater strength to the braid without significantly increasing the device delivery profile, with the thinner wires offering some strength while filling out the braid matrix density.
The wire is preferably NiTi alloy that is superelastic at body temperature. The metal may be a binary alloy or a ternary alloy to provide additional radiopacity. Alternatively, radiopaque platinum fibers may be included in the braid, or the wire may comprise platinum or gold core Nitinol DFT. Otherwise, hubs, bands or wraps (preferably Pt) used to secure the braid wire (at either or both distal and proximal ends, and also in between caps where appropriate) may serve as the sole radiopaque feature(s).
To improve implant wire corrosion resistance and/or biocompatibility after heat setting shape, the implants may be etched in “AYA” Sulfamic Acid solution, then passivated in Nitric acid solution. Alternatively or additionally, pre-etched and/or polished wire may be employed in braiding the implant matrix. Shape setting the braid in the implant shape may be performed in an oven/furnace, a fluidized bath or salt pot. All such processing is within ken of those with ordinary skill in the art.
Especially after heatsetting the shape, the wire may be coated with an agent for promoting a desired biological effect. For example, wire can be coated with a thrombogenic or an endothelization agent, or other agent capable of promoting a desired biological process at the target site. The braid balls may also be partially or fully coated on the exterior (e.g., with coating such as urethane) to increase the occlusive effect of the ball, provided the coating does not cause the delivery profile of the final device to exceed allowed limits. Hydrogel coating also offers an appealing option, such as a hydrogel-based polymer network capable of entrapping therapeutic agents as described in U.S. Pat. No. 6,905,700 to Won et al.
Likewise, while the balls advantageously comprise Nitinol braid, the braid may instead comprise polymer—especially high strength biodegradable polymer such as MX-2 (MAX-Prene), synthetic absorbable monofilament (90/10 Glycolide/L-Lactide) and/or G-2 (Glycoprene), synthetic absorbable monofilament (Glycolide (PGA), ε-Caprolactone (PCL), Trimethylene Carbonate (TMC) Copolymer) that is heat set into shape (e.g., at 110 degrees centigrade for an hour).
Deliverability of the subject implants to certain neurovascular sites (e.g., distal intercranial aneurysms) often requires that they be compressible to pass through a catheter sized for navigating the narrow and tortuous vessels of the brain. Standard neurovascular catheters suitable for such use have 0.021″ and 0.027″ lumen diameters. Especially for higher wire count balls 0.027″ ID (e.g., Cordis Mass Transit Boston Scientific Renegade HI-FLO) or larger (e.g., 0.044″ ID Concentric Merci Distal Access Catheter) commercially available micro catheters may be preferred. For devices adapted to address PVO indications in which higher wire counts and/or larger wire diameters are used to ensure anchoring, the implants may require 5 and/or 6 Fr guide catheters for delivery.
In any of the configurations described, the devices may comprise high-density Nitinol braid that is folded/doubled-back upon itself and heatset to provide an open body having two adjacent layers forming an even denser matrix to occlude blood flow. The folded-back (inverted or everted) section may be closed to define a distal end of the device where a radiopaque feature may be located. At the opposite side of the implant, braid filaments are held in a hub including at least an outer band.
A port within the hub can receive component(s) of an optional detachable pusher. Alternatively, the implant can be deployed through a catheter using a simple pusher. Braid filaments within the hub(s) may be welded to each other and/or the band. Alternatively, the braid and hub(s) may be secured using biocompatible adhesive.
In a relaxed state, the implants define an open, preferably rounded, volume. In a delivery catheter, they compress into a substantially cylindrical body. When deployed at a treatment site, they expand to abut surrounding tissue and occlude flow in a clinically relevant timeframe.
Use of a detachable pusher allows for deploying a device (e.g., in an aneurysm) and checking fit. Deployed in an aneurysm to occlude the aneurysm at its neck, the implant device largely assumes the shape of the aneurysm, with the proximal hub and closely adjacent braid material outside the neck. To achieve such fit, the implants are provided in a range of sizes. These may progress in 0.5 mm to 1 mm diameter increments. For aneurysm treatment at bifurcations, it may also be desirable if the ball (at least in its delivered configuration) assumes a tear-drop shape to assist in a flow-divider/diverter type function as described in Dieck, et al., referenced above.
Should the selected implant not fit as desired, however, it can simply be withdrawn back into the delivery catheter. If desired fit is achieved (with the first implant or a replacement) as confirmed by medical imaging, the implant is released.
An electrolytically-releasable GDC-type joint can be used hold the implant secure to the pusher until release. Details regarding suitable electrolytic detachment systems can be appreciated and applied to the current system as taught in U.S. Pat. No. 5,122,136 to Guglielmi and continuing applications thereof—all of which are herein incorporated by reference. Another electrically-powered detachment approach employs a meltable fiber or suture junction connecting the implant to the delivery pusher/guide. In such a system, a polymeric core may be configured with helically wound conducting ribbons held to the core. Upon application of voltage, sufficient current is conveyed through the ribbons to a wire bridge connecting them. Heat generated along the bridge, optionally NiChrome wire, severs the suture that is tied onto or running adjacent to the bridge in order to release the implant. Further details of a suitable suture-melt detachment systems are described in the incorporated provisional applications.
Yet, mechanical detachment systems may be more preferred. An aspect of the present invention involves pushers in which at least one member provides mechanical interference at/with the implant hub port to releasably lock the implant onto the pusher. In one approach, a wire or ribbon exiting an extension of the pusher threaded through the port produces such interference until it is withdrawn. In another example, a plurality of wires/ribbons are received through the port. One or more (typically two or three) of these wires extend through a pusher catheter body to a proximal handle interface. A final “anchor” wire received through the port may also extend to the handle. The anchor wire includes a head sized to exit the hub port only after the other “control” wires are cleared therefrom. The head is preferably formed by laser or plasma heating/melting. The handle provides a user interface to first remove the control wires, and then (optionally) also pull the final anchor wire.
To assist in implant recapture should it not be released, a smooth lead-in/trumpet shaped recapture profile may be provided between the hub and main body of the implant. In another approach relevant in a two-layer implant, no such profile is provided. Rather only the outer of braid layer is secured within the hub, and the inner layer “floats”. In this way, only the outer layer must be straightened relative to the hub to retrieve the ball within the catheter/sheath, with the inner layer riding along.
In order to permit such action, the braid matrix must remain stable and interlocked. Accordingly, when feasible, a one-over-one braid pattern will be preferred. In addition, the braid should be trimmed adjacent the hub where the hub-secured braid is most dense. So configured, the outer braid both serves as a guide and is of such density to prevent loose ends of the inner layer from poking through. Whereas a floating-layer type ball implant would typically only be used for an aneurysm indication due to reduced radial strength, the recapture profile may be used on either an implant intended for aneurysm or PVO use.
Recapture features aside, when deployed in a vessel for use in parent vessel occlusion, the subject implant is “sausage” shaped. For such purposes, it may be desirable that the compressed length of the ball is minimized relative to its diameter. Proximal and/or distal ends of the ball may be flattened or flatter (such that the ball is more “donut” shaped) for this purpose.
Oversizing the device relative to the vessel provides adequate radial force to anchor its position against blood flow/pressure. To generate more anchoring force within a vessel for a PVO-dedicated implant (i.e., of a given deployed length), the ball may be formed in a shape having an elliptical cross-section. To offer further improved vessel anchoring, a cylindrical waist may be incorporated in the shape. Edges formed will concentrate stresses on the vessel wall in some cases to improve anchoring. Yet, the bulk shape allows the implant to work within a wide range of vessel sizes. Indeed, one size may fit a wide range of vessel diameters (e.g., a 10 mm ball suitable for 3-5 mm vessels, etc.).
In either type of implant (i.e., aneurysm or PVO), an advantageous construction involves folding or doubling-back the braid during manufacture to produce a two-layer matrix. A medial crease or fold in the braid is formed that is used in defining one end of the implant.
The fold may be pre-set in the braid or formed when fixturing the braid for shape setting. In the former case, the bend is pre-set by heatsetting the braid when confined in a tight tubular shape (e.g., by a crimper or at least partially within a hypotube). In the latter case, the braid is tied with suture at a point, a form is inserted in the open end of the braid tube and the braid is stretched, or positioned, over the form with the folded section under compression. When heated to set the shape, the suture burns away as the compression force sets the fold at a minimal radius.
The fold itself proves useful in a number of ways. In one variation of the invention, the folded section provides an atraumatic end to the implant. The folded section can be left open, or tied closed by a suture, wire (or other material) loop. If not radiopaque itself, the tie may also hold a marker band (knotted, glued or crimped on). If such a marker is provided, it may advantageously be suspended adjacent the top/distal end of the ball within the interior volume.
Either way, upon compression to a delivery profile, the implant body basically pivots (rather than bends) at the fold, thus minimizing in-catheter/sheath forces. This improves device trackability as well as delivery and the ability to recapture if treatment with another size device is desirable.
In a PVO-specific implant, a marker band can be held between braid layers adjacent the medial fold. The band is securely captured and “hidden” without presenting edges or other features. As such, the distal end of the device offers a smooth delivery/tracking profile without need to otherwise secure the band.
Utilized in any such fashion (i.e., open, tied or banded), joints and other delivery profile-increasing features are avoided at one end of the ball. As such, the fold offers constructional advantages (including improved manufacturability)—as well as reducing areas for failure where ends of the braid would otherwise need to be secured. Moreover, the doubled-over tubular stock achieves excellent density while ensuring consistent compression and shape-recovery performance since the layers are well matched. So-matched, they extend/foreshorten to substantially an equal degree when exiting and (re)entering the catheter.
One variation of the invention takes advantage of the matched braid layers, and simply eliminates the fold by grinding or otherwise cutting it away after heatsetting (and, optimally, braid hub securement). So-prepared, the implant becomes more radially compliant as may be desirable for aneurysm treatment. And without any additional space taken-up by the bend in the filaments, the ball can be further compressed for delivery through the smallest microcatheters (for a given braid density) to achieve access to more distal treatment sites.
Another variation of the invention may or may not be constructed using a folded-over approach. To achieve higher braid densities without stacking up additional layers having to fit within the microcatheter lumen, additional “cap” structures can be instead incorporated in the implant. For delivery, these features neck-down or compress in series. Yet, upon exit from the microcatheter, they recover to a position adjacent the main body of the implant.
The ball body and cap portions of the implant are typically constructed from a continuous section of braid. Intermediate marker sections may be provided between the elements. A hub including a delivery system port is provided at the proximal end of the device.
The proximal caps of braid provide additional braid layers to the device at an end where occlusion of blood flow is critical. The proximal end of a ball placed in an aneurysm contacts the opening and neck of the aneurysm. To achieve greater flow occlusion, the braid caps can be single or double layer braid. One or more braid caps can be placed at the proximal end of the ball (i.e., a braid ball can have up to three braid caps, and more if feasible).
The braid caps do not function, and are not adapted to function, as anchors for the device. An anchor holds fast or checks motion of an object attached to it. To anchor something is to fix or fasten, or affix firmly an object. The balls implants are not anchored in the aneurysm or parent vessel using the braid caps. Rather, the braid caps are designed to either be adjacent the ball within an aneurysm or to fill only the neck region. In either case, the caps do not substantially engage vascular tissue adjacent the ball. They serve as occlusive elements that enhance the ball's embolic potential.
As alluded to, two types of capped braid ball implants are provided. Caps adapted to fit only in the aneurysm neck are typically round (though they may be oval) and may be offered in a variety of sizes to fit different neck sizes just as the ball portion of the implant is offered in different sizes. In other words, across a whole line of implants, each of the cap size and ball size parameters may be varied.
The caps adapted to fit in an aneurysm adjacent the ball portion of the implant are larger and shaped to conform to the ball-shaped body. Their delivery requires either compressing the ball portion of the implant within the aneurysm and deploying the cap therein, or deploying the cap outside the aneurysm and pushing it into the aneurysm in a deployed state.
Delivery of the devices with the neck-filling cap(s) or disk(s) is performed substantially the same as braid balls without such feature(s) with the exception that the delivery catheter is withdrawn further to expose the cap(s) or the catheter is stationed outside the aneurysm neck (vs. at the neck) and the implant extruded therefrom. Of course, some combination of such activity may alternatively be employed.
In any case, if the desired fit is achieved, the implant is released. Otherwise, the implant is pulled into the delivery catheter from the proximal hub. The one or more caps compress to the linear profile of the delivery/retrieval sheath, followed by the ball portion.
In yet another variation of the invention, a braid-ball is used in conjunction with a stent. The ball may be attached to a stent, with them delivered together. Alternatively, a frame or cage may be provided at the end of a stent into which the braid-ball is delivered after the stent is in place. In either case, the ball and/or frame may be sized to fill substantially all of an aneurysm or only fill the neck. Either way, the stent will serve as an anchor to prevent the ball from migrating. The frame-plus-ball solution offers certain advantages in terms of staged deliverability, whereas the ball-topped stent offers a one-shot solution achievable in a single delivery. In each example, the stent may be either self-expanding (e.g., comprising superelastic Nitinol) or balloon-expandable (e.g., comprising stainless steel and mounted on a PTCA-type balloon). Regardless, the braid-ball implant employed may be any one of those described in the present filing or those cross-referenced above.
The present invention includes the subject devices, kits in which they are included, methods of use and manufacture. A number of aspects of such manufacture are discussed above. More detailed discussion is presented in connection with the figures below.
The figures provided herein are not necessarily drawn to scale, with some components and features are exaggerated for clarity. Of these:
Variations of the invention from the embodiments pictured are contemplated. Accordingly, depiction of aspects and elements of the invention in the figures is not intended to limit the scope of the invention.
Various exemplary embodiments of the invention are described below. Reference is made to these examples in a non-limiting sense. They are provided to illustrate more broadly applicable aspects of the present invention. Various changes may be made to the invention described and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process act(s) or step(s) to the objective(s), spirit or scope of the present invention. All such modifications are intended to be within the scope of the claims made herein.
Turning to
Implant 20 is set within an aneurysm sac 2 at a vascular bifurcation 4. It is delivered by access through the trunk vessel 6 (e.g., the basilar artery), preferably through a commercially available microcatheter (not shown) with a delivery system as detailed below.
The size of the implant may be selected to fill and extend somewhat out the neck 10 of the aneurysm so the proximal end 22 of the device helps direct blood flow along the surface of the braid from which it is constructed to the branch vessels 8. A distal end of the ball is dome-shaped adjacent a fold 24 in the braid resulting in a two-layer 26, 28 (inner and outer layer, respectively) construction at least where impacted by flow at the neck 10 of the aneurysm. As shown, one or more turns of a coil 30 (e.g., Pt wire) or a band (not shown) may provide a distal radiopaque feature to mark the location of the implant.
The fold 24 in the braid is set at a tighter radius in the implant 40 shown in
As more easily seen in
Tie 44 may comprise any biocompatible material including Stainless Steel, Titanium, Nitinol (possibly wire that is martensitic at body temperature—commonly referred to as “muscle wire”), suture, etc. An advantage of utilizing wire is that it may simply be twisted to secure its position, along with the marker. In any case, the tie filament should be thin (e.g., about 0.0015 inch diameter or less) if a minimum-radius fold is desired.
Another salient feature of implant 40 concerns the region adjacent hub 42. Specifically, a flared or trumpet-shaped recapture profile 52 is set in the braid to aid in device recapture into the delivery catheter through which the device is advanced. An access port 54 is provided within the hub. This port accepts a delivery system interface. Delivery system construction as well as further optional details of the implant are provided below.
Of course,
Depending on the desired fit, the implant selected by the physician may turn out to be not exactly the right size upon delivery due to variability of aneurysm morphology and/or limitations of medical imaging. It is then that the recapture profile is most useful by facilitating implant retrieval. The first implant can be discarded in favor of a second with a more appropriate size.
In the three examples provided, it is notable that a consistent pore size is maintained toward the center of the ball. Generally it will be desirable to minimize overall pore size. However, the density of the braid that can be achieved in braiding a given tube of braid stock is limited by its diameter and wire size. Accordingly, each of the three balls shown is made of braid incorporating a different number of wires or “ends”. For example, the first implant 60 may be produced from folded-over 72-end material braided over a 6 mm diameter mandrel, the second implant 62 made of folded over 96-end braid from an 8 mm mandrel, and the third implant 64 made of folded-over 144-end braid made on a 10 mm mandrel. Alternately, the larger implants (i.e., those around 10 mm in diameter) may also be made of 96-end braid in order to maintain a lower crossing profile. Specifically, 0.027 inch catheter crossing profile can be achieved when using 96-end braid made of 0.001″ diameter wire. Likewise, at the smaller end of the range (e.g., around 5 mm in diameter) 64-end braid may instead be selected to achieve 0.021 inch crossing profiles.
In any case, braid filaments are shown in pairs within these implants—one from each layer 26, 28. While the organization of the braid is often more random, the double/dual layer construction—on average—results in higher density than might be achieved with a single-layer implant due to limitations on braid density for a given starting diameter of braid.
The implants 70, 72 shown in
Either way, the implants include unique proximal-end configurations. In addition to a ball or bulbous portion 80, each implant includes a flap 76 intended to improve its blood flow disruption potential. Flap 76 included in implant 70 is intended for intra-aneurysmal use. To deliver it as shown, the ball or bulbous portion is first delivered into the aneurysm sac 2. Then, that portion of the device is compressed while still mounted to pusher 100 to deploy the flap section therein. After final positioning is achieved as shown in
The implant in
As pictured, the ball-and-disk variation of the implant shown in
While understood better in the context of the implant manufacture steps below, flap 76 may be formed using a simple washer or plate over which the braid is heat set. Otherwise, the forming tool may be curved or dished so that flap 76 better follows the contour of the main implant body.
Flap 76 in the
The frame may comprise a plurality of individual wires 126 secured to a hub 128 of the stent at a proximal end and another hub or platten 130 at the distal end. In another variation, the wires making up the frame are cut from the same tube as the stent cells and any included hub. They may terminate at a distal end within a hub, be swaged within a radiopaque band, welded together, secured by adhesive, or attached by some other means. In any case, they are typically (though not necessarily) attached to form a closed frame. Still, an open frame is contemplated—especially one in which the wires hook backwards (i.e., proximally) to help “catch” the ball when emplaced.
These devices (i.e., those illustrated in
While the stents advantageously include three support extensions 136 for the ball or ball cage, more or fewer may be employed. However, the use of three offers the minimal stable structure available. And where they come together, they operate much like a universal joint to help end-mounted ball/frame successfully interface with the aneurysm to be treated.
In this side-sectional view, the braid matrix is shown inverted (or everted) at fold 24. A band 144 is set between the inner and outer braid layers. The band closes the end and servers as a marker (especially when it comprises Pt). An adhesive compound 146 (e.g., LOCTITE 3311 or 4014) may be used to fill any residual lumen within the fold aperture. As with the other implants (including those in
Otherwise, both ends of the implant may be closed/plugged with an adhesive or otherwise. Without a delivery system access port, the implant may be delivered using a simple pusher (vs. being fully retrievable and/or repositionable). So-configured, no proximal hub is required either. Indeed, the braid may simply be trimmed and shape set to come together and/or be secured by welding, adhesive or otherwise at the proximal end.
Another optional aspect of the invention is illustrated in
In any case, because of the original construction technique utilizing one tube of braid and folding it over to produce two layers, the (now-separated) layers are well matched to predictably expand and contract. Moreover, once any profile-limiting bends are removed (e.g., by cutting, grinding, etc.) the layers can be reconnected if the adjustability feature described above is not desired. A urethane coating layer 144 or other adhesive (advantageously including radiopaque Barium or Tantalum powder) may be used locally to accomplish such action without a resulting increase in delivery profile.
Still, maintaining the fold in an implant offers numerous advantages in other circumstances—especially when it is formed in such a manner that minimizes wire bend radius/profile. Namely, implants including the fold may offer better size integrity and radial force in circumstances when desired, eliminate any loose fibers at an end of the implant without further processing (such as by polymer application), provide a pocket for a marker and/or tie to suspend a marker, etc.
Moreover, it is to be recognized that the folded end of the implant will not necessarily be set at the distal end of the device. Rather, the folded section 24 may be utilized at a proximal side as shown in
In any case,
In these figures,
In
After any such shape-setting, a device perform 220 is ready once the internal form is finally removed as illustrated in
If the implant is formed from braid that includes an oxide layer, the perform is next etched, then passivated. However, if pre-etched wire is employed in braiding and any heatsetting performed in a salt pot, vacuum furnace, or using other equipment to minimize oxide formation, the perform may simply be subject to Nitric acid passivation.
Even if additional intermediate process steps are employed,
An alternative approach to compression-forming the fold during perform shaping to achieve a minimum radius bends in the braid wire is presented in
So-shaped, the overall implant may be formed largely as described in connection with
Pre-treating the fold or compression forming it during heatsetting the bulk of the implant is advantageous especially for those cases in which the region adjacent the fold is to be dome shaped. However, when a nubbin is acceptable in the device design given its intended use (e.g., PVO)
As for setting the remaining shape of the implant or its perform 220,
The implant shown in
Both implants still share a flattened/reduced aspect ratio relative the spherical ball implants previously pictured. Such an aspect ratio allows for greater oversize for anchoring the self-expanding implants in vessel for a resulting length of device. This fact is advantageous given that the focal length of occlusion is often important in treating neurovascular defects in order to inadvertently block adjacent perforator/branch vessels in PVO applications.
Whatever the form of the implant, when a hub is included to secure the braid filaments, certain affixation challenges must be addressed. The hub must be securely fastened to the braid and it may be necessary to minimize the length of the feature.
Especially when utilizing laser energy, an alternative approach as illustrated in
The adhesive may be applied evenly around the braid by rotating the assembly as indicated. Other approaches may be utilized as well. In one such approach a plurality of optional access windows 282 may be included in the band to receive and disperse adhesive. Adhesive is also optionally wicked away from the braid 200 by a paper card or absorptive fiber pad 284 (or removed by other means) so that any excess of wicking/flowing adhesive utilized to ensure braid lumen coverage and/or band 50 adhesion does not interfere with the self-expanding action of the implant body 224.
Use of an inner band 276 is also optional. While it occupies space that the braid-and-glue only lumen conserves, including an inner band in the hub assembly 42 may sometimes be desirable for the detachment system interface.
Use of an adjunct hypotube 286 is also optional. This tube, however, offers a useful grip or handle on which to clamp for subsequent trimming. Especially for such use, a thick-walled (e.g., about 0.005″ or greater) tube may be desirable because of additional stability it will yield. As with the band which becomes part of the implant, hypotube 286 may include one or more access windows 282 for adhesive application.
For trimming an implant perform 220 (however it is shaped),
After the cut is made, the hub length may be further reduced by grinding its face. After mandrel removal (also cut-off in the trimming procedure) and cleaning in an ultrasonic bath, the hub face may be sealed with adhesive.
Produced using any of the referenced hubbing techniques, another implant variation 300 is illustrated in
The implant differs from those discussed above in that it includes a layer of braid that is not secured at each end of the device. Rather, the inner layer 26 “floats”. Its presence augments implant density, but its fibers adjacent the hub 42 are not forced to bend when the ball is compressed in a sheath for delivery and/or recapture. As such, relatively less force is required for recapture, even when the braid is bent at approximately 90 degrees upon exiting the hub (i.e., without the proximal end of the implant body 224 including a recapture profile in the design).
To produce a ball with the inner braid ends 302 proximate to the hub where the density of the outer braid is highest and best able to prevent individual filaments from the inner layer poking through the braid matrix, an elegant set of manufacturing steps are carried out. Specifically, after starting with an implant perform 220 as shown in
Such further process may include banding/hubbing, trimming and/or tying the fold aperture closed. However, such tying may advantageously be performed prior to restoring the position of the outer braid while the fold 24 is exposed per
Whatever techniques are employed in their construction, the implants are advantageously mounted to a releasable pusher. Delivery system 308 in
To allow release, the core member is withdrawn into hypotube 310 clearing each of the windows 314 by pulling finger grip 322. At which point, the hypotube may exit the hub port 54 by withdrawing the pusher.
Another detachable delivery system 330 is illustrated in
The control wires 332 may extend to or past the anchor wire head 334 (the former case illustrated in
In any case, each of the pusher sleeve lumen 340 and the implant hub lumen/port 54 is preferably sized so that the wires (control wires 332 and anchor wire 336) are received in a close-packed arrangement. In this manner, the implant and pusher sleeve serve as a guide eliminating loading difficulties associated with the wires becoming braided or entwined. Also for loading the system, the anchor wire is typically tensioned to a very slight degree (prior to simple gluing into a handle or using a bias spring incorporated in the handle design) to ensure any gap between the implant and pusher is closed and remains closed in use.
Finally,
After removal from sterile packaging (not shown), the implant is pulled into the loading sheath 352. The loading sheath is received within the hub of the catheter to be used for implant delivery and the implant is advanced into the catheter. Then, the implant may be advanced to and deployed at a treatment site. Or it may be retrieved in exchange for another size implant, else repositioned if desired prior to ultimate detachment like that illustrated in
The subject methods may include each of the physician activities associated with implant positioning and release. As such, methodology implicit to the positioning and deployment of an implant device forms part of the invention. Such methodology may include placing an implant within a brain aneurysm, or at parent vessel targeted for occlusion, or other applications. In some methods, the various acts of implant introduction to an aneurysm or parent vessel are considered.
More particularly, a number of methods according to the present invention involve the manner in which the delivery system operates in reaching a treatment site, for example. Other methods concern the manner in which the system is prepared for delivering an implant, for example attaching the braid ball to the delivery system. Any method herein may be carried out in any order of the recited events which is logically possible, as well as in the recited order of events, or slight modifications of those events or the event order.
Also, it is contemplated that any optional feature of the inventive variations described may be set forth and claimed independently, or in combination with any one or more of the features described herein. Reference to a singular item, includes the possibility that there is a plurality of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “an,” “said,” and “the” include plural referents unless specifically stated otherwise. In other words, use of the articles allow for “at least one” of the subject item in the description above as well as the claims below. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.
Without the use of such exclusive terminology, the term “comprising” in the claims shall allow for the inclusion of any additional element irrespective of whether a given number of elements are enumerated in the claim, or the addition of a feature could be regarded as transforming the nature of an element set forth in the claims. Except as specifically defined herein, all technical and scientific terms used herein are to be given as broad a commonly understood meaning as possible while maintaining claim validity.
The breadth of the present invention is not to be limited to the examples provided and/or the subject specification, but rather only by the scope of the claim language. Use of the term “invention” herein is not intended to limit the scope of the claims in any manner. Rather it should be recognized that the “invention” includes the many variations explicitly or implicitly described herein, including those variations that would be obvious to one of ordinary skill in the art upon reading the present specification. Further, it is not intended that any section of this specification (e.g., summary, detailed description, abstract, field of the invention) be accorded special significance in describing the invention relative to another or the claims. All references cited are incorporated by reference in their entirety. Although the foregoing invention has been described in detail for purposes of clarity of understanding, it is contemplated that certain modifications may be practiced within the scope of the appended claims.
Especially for aneurysm treatment, but also for either one of the aforementioned treatments, the form of the ball is very important. In particular, the density of the device is paramount in applications where braid itself is intended to moderate or stop blood flow—allowing thrombosis within a volume formed by the ball.
According to the present invention, braid-ball type implants are provided in braid of sufficient density to moderate blood flow within the volume of the implant. Upon thrombosis, flow thereto is stopped. Alternatively, a blood-barrier covering can be applied to the filamentary structure to immediately stop blood flow into the vascular site, in which the implant volume is set.
In either case, to form thrombosis within the volume of the ball, the filaments of the braid matrix permit filling of the implant with blood when emplaced at a vascular treatment site. This blood then thromboses due to the flow-disruption effect(s).
Unlike Nitinol tube-cut cages that may be suitable for (or assist) in coil retention, the ball devices are adapted to work alone—or in combination with each other to effect a complete treatment. As such, high density braid/mesh is typically required. Namely, braid having at least about 48 ends, typically set at about 90 degrees or greater, in diameters from about 4 to about 8 mm may be employed. At larger diameters (e.g., about 6 to 12 or more), more wire ends (e.g., 64, 72 and upwards) may be employed in forming the balls.
Suitable braid for constructing the balls may be obtained from Secant Medical, Inc. Wire diameters may be in the range of about 0.001 to about 0.003 inches, depending on desired delivery profile (which is typically less than about 0.050 inches). The braid forming the balls may incorporate only one size wire, or may be formed with multiple sizes.
The wire is preferably superelastic NiTi alloy. The metal may be a binary alloy or a ternary alloy to provide additional radiopacity. Alternatively, radiopaque platinum fibers may be included in the braid, or the wire may comprise platinum or gold core Nitinol DFT. Otherwise, wraps or bands (preferably Pt) used to secure the braid wire may serve as the sole radiopaque feature(s).
In any case, the construction approaches described herein enable producing these useful devices. Whether comprising braid alone, or incorporating some further blood-barrier covering (such as a thin urethane film as may be applied by Hantel, Inc. or others), the use of braid presents numerous challenges in managing the termination of multiple wires and in forming the desired structures.
Also included in the invention are detachable implant pushers that utilize a resistance wire heater to thermally sever a suture associated with the implant to effect release. As distinguished from known approaches where an implant is retained by a loop connected back to a delivery system pusher that is withdrawn with the delivery system, the present invention contemplates a leave-behind tether.
Further details, variations, modification and optional features of the invention may be appreciated by review of any of the incorporated patent applications. However, the priority date and subject matter included in the appended claims rely solely on the subject matter filed in U.S. Provisional Patent Application Nos. 61/046,670 and 61/046,594, the earliest patent applications (each filed Apr. 21, 2008) on which U.S. patent application Ser. No. 12/427,620 relies. Selected figures from the '670 and '594 application and all of text from the '594 application—all—incorporated by reference in the parent application hereto is reproduced herein.
Implants
Referring to
As single layer of the braid is provided in which ends of the braid are secured and managed to provide an atraumatic interface. Specifically, ties 410 (as illustrated in
In the implant variation pictured, the expanded configuration defines an ovoid or roughly spherical shell 418 that is permeable to blood. The braid defining the proximal and distal ends of the implant turns or curves inward to a point where it is secured within the periphery of the shell.
The inversion of the braid provides recessed securement of the braid resulting in atraumatic ends of the implant. The braid filaments optionally extend beyond the securing/securement features in order to define wire filament “tufts” 420 that will further promote thrombosis of blood that enters the ball upon deployment within a patient's vasculature. However configured in regard to braid filament end securement and termination, inset ends of the braid (proximal and distal insets 422/424, respectively) are demonstrated when the implant is in an expanded state to fill an aneurysm 426 off of a vessel 428.
Delivery Systems
Methods of Manufacture
Included in the invention is a method of manufacture including tying-off or otherwise securing a second end of a braid within an interior volume of a ball where other approaches would be impracticable. The technique may be employed in creating the balls (be they spherical or ovaloid in cross-section, etc.) out of one continuous section of braid. In so doing, joints and other delivery profile-increasing features are avoided—as well as potential areas for failure. Accordingly, the subject implants are extremely robust and fully recoverable to their aneurysmal shape as is required when they are delivered through a catheter in low profile. Robust shape recovery is required in treatments targeting distal vasculature, especially the tortuous neurovasculature encountered in human brains.
A detailed example of one process path for implant formation is illustrated in
Additional refinement to the shape over that shown in
Methods of Use
Any one of the subject implants is delivered to a target site employing known percutaneous catheter access techniques. The implant may be secured to a pusher (e.g., pusher 430) used to advance it through the access catheter (e.g., microcatheter 444). Upon emplacement at the treatment site (e.g., cerebral aneurysm 426 as illustrated in
The present application is a continuation of U.S. patent application Ser. No. 16/893,431, filed Jun. 4, 2020, which is a continuation of U.S. patent application Ser. No. 15/415,669, filed Jan. 25, 2017, which is a continuation of U.S. patent application Ser. No. 13/470,013, filed May 11, 2012, now U.S. Pat. No. 9,585,669, which is a continuation of U.S. patent application Ser. No. 12/911,034, filed Oct. 25, 2010, now U.S. Pat. No. 9,039,726, which is a continuation of U.S. patent application Ser. No. 12/427,620, filed Apr. 21, 2009, now U.S. Pat. No. 8,142,456, which claims the benefit of each of: U.S. Patent Application Ser. Nos. 61/046,594 and 61/046,670, both filed Apr. 21, 2008; U.S. Patent Application Ser. Nos. 61/083,957 and 61/083,961, both filed Jul. 28, 2008; and U.S. Patent Application Ser. No. 61/145,097, filed Jan. 15, 2009. Each of the foregoing applications is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3108593 | Glassman | Oct 1963 | A |
4425908 | Simon | Jan 1984 | A |
4619246 | Molgaard-Nielsen et al. | Oct 1986 | A |
4655771 | Wallsten | Apr 1987 | A |
4768507 | Fischell et al. | Sep 1988 | A |
4921484 | Hillstead | May 1990 | A |
4998539 | Delsanti | Mar 1991 | A |
5026377 | Burton et al. | Jun 1991 | A |
5061275 | Wallsten et al. | Oct 1991 | A |
5064435 | Porter | Nov 1991 | A |
5104404 | Wolff | Apr 1992 | A |
5122136 | Guglielmi et al. | Jun 1992 | A |
5158548 | Lau et al. | Oct 1992 | A |
5222971 | Willard et al. | Jun 1993 | A |
5250071 | Palermo | Oct 1993 | A |
5284488 | Sideris | Feb 1994 | A |
5326350 | Li | Jul 1994 | A |
5334210 | Gianturco | Aug 1994 | A |
5354295 | Guglielmi et al. | Oct 1994 | A |
5378239 | Termin et al. | Jan 1995 | A |
5405379 | Lane | Apr 1995 | A |
5417708 | Hall et al. | May 1995 | A |
5425984 | Kennedy et al. | Jun 1995 | A |
5499981 | Kordis | Mar 1996 | A |
5527338 | Purdy | Jun 1996 | A |
5545208 | Wolff et al. | Aug 1996 | A |
5545209 | Roberts et al. | Aug 1996 | A |
5549635 | Solar | Aug 1996 | A |
5624461 | Mariant | Apr 1997 | A |
5634942 | Chevillon et al. | Jun 1997 | A |
5645558 | Horton | Jul 1997 | A |
5662703 | Yurek et al. | Sep 1997 | A |
5669931 | Kupiecki et al. | Sep 1997 | A |
5690671 | Mcgurk et al. | Nov 1997 | A |
5702419 | Berry et al. | Dec 1997 | A |
5713907 | Wholey et al. | Feb 1998 | A |
5725552 | Kotula et al. | Mar 1998 | A |
5728906 | Eguchi et al. | Mar 1998 | A |
5733294 | Forber et al. | Mar 1998 | A |
5741333 | Frid | Apr 1998 | A |
5749891 | Ken et al. | May 1998 | A |
5749895 | Sawyer et al. | May 1998 | A |
5749919 | Blanc | May 1998 | A |
5749920 | Quiachon et al. | May 1998 | A |
5766151 | Valley et al. | Jun 1998 | A |
5814062 | Sepetka et al. | Sep 1998 | A |
5823198 | Jones et al. | Oct 1998 | A |
5830230 | Berryman et al. | Nov 1998 | A |
5846261 | Kotula et al. | Dec 1998 | A |
5853422 | Huebsch et al. | Dec 1998 | A |
5855578 | Guglielmi et al. | Jan 1999 | A |
5879366 | Shaw et al. | Mar 1999 | A |
5908435 | Samuels | Jun 1999 | A |
5911731 | Pham et al. | Jun 1999 | A |
5916235 | Guglielmi | Jun 1999 | A |
5925060 | Forber | Jul 1999 | A |
5928228 | Kordis et al. | Jul 1999 | A |
5928260 | Chin et al. | Jul 1999 | A |
5935148 | Villar et al. | Aug 1999 | A |
5935362 | Petrick | Aug 1999 | A |
5941249 | Maynard | Aug 1999 | A |
5944738 | Amplatz et al. | Aug 1999 | A |
5951599 | Mccrory | Sep 1999 | A |
5957948 | Mariant | Sep 1999 | A |
5964797 | Ho | Oct 1999 | A |
5976162 | Doan et al. | Nov 1999 | A |
5976169 | Imran | Nov 1999 | A |
5980554 | Lenker et al. | Nov 1999 | A |
6001092 | Mirigian et al. | Dec 1999 | A |
6010517 | Baccaro | Jan 2000 | A |
6022374 | Imran | Feb 2000 | A |
6024756 | Huebsch et al. | Feb 2000 | A |
6033423 | Ken et al. | Mar 2000 | A |
6036720 | Abrams et al. | Mar 2000 | A |
6059813 | Vrba et al. | May 2000 | A |
6063070 | Eder | May 2000 | A |
6063104 | Villar et al. | May 2000 | A |
6086577 | Ken et al. | Jul 2000 | A |
6090125 | Horton | Jul 2000 | A |
6093199 | Brown et al. | Jul 2000 | A |
6096021 | Helm et al. | Aug 2000 | A |
6096034 | Kupiecki et al. | Aug 2000 | A |
6096073 | Webster et al. | Aug 2000 | A |
6099526 | Whayne et al. | Aug 2000 | A |
6106530 | Harada | Aug 2000 | A |
6110191 | Dehdashtian et al. | Aug 2000 | A |
6123715 | Amplatz | Sep 2000 | A |
6139564 | Teoh | Oct 2000 | A |
6152144 | Lesh et al. | Nov 2000 | A |
6159531 | Dang et al. | Dec 2000 | A |
6165193 | Greene, Jr. et al. | Dec 2000 | A |
6168592 | Kupiecki et al. | Jan 2001 | B1 |
6168615 | Ken et al. | Jan 2001 | B1 |
6168618 | Frantzen | Jan 2001 | B1 |
6168622 | Mazzocchi | Jan 2001 | B1 |
6183495 | Lenker et al. | Feb 2001 | B1 |
6190402 | Horton et al. | Feb 2001 | B1 |
6193708 | Ken et al. | Feb 2001 | B1 |
6221086 | Forber | Apr 2001 | B1 |
6238403 | Greene, Jr. et al. | May 2001 | B1 |
6261305 | Marotta et al. | Jul 2001 | B1 |
6280412 | Pederson, Jr. et al. | Aug 2001 | B1 |
6299619 | Greene, Jr. et al. | Oct 2001 | B1 |
6306141 | Jervis | Oct 2001 | B1 |
6309367 | Boock | Oct 2001 | B1 |
6322576 | Wallace et al. | Nov 2001 | B1 |
6325820 | Khosravi et al. | Dec 2001 | B1 |
6331184 | Abrams | Dec 2001 | B1 |
6332576 | Colley et al. | Dec 2001 | B1 |
6342068 | Thompson | Jan 2002 | B1 |
6344041 | Kupiecki et al. | Feb 2002 | B1 |
6344048 | Chin et al. | Feb 2002 | B1 |
6346117 | Greenhalgh | Feb 2002 | B1 |
6350270 | Roue | Feb 2002 | B1 |
6361558 | Hieshima et al. | Mar 2002 | B1 |
6364895 | Greenhalgh | Apr 2002 | B1 |
6368339 | Amplatz | Apr 2002 | B1 |
6371980 | Rudakov et al. | Apr 2002 | B1 |
6375668 | Gifford et al. | Apr 2002 | B1 |
6379372 | Dehdashtian et al. | Apr 2002 | B1 |
6383174 | Eder | May 2002 | B1 |
6391037 | Greenhalgh | May 2002 | B1 |
6409750 | Hyodoh et al. | Jun 2002 | B1 |
6428558 | Jones et al. | Aug 2002 | B1 |
6443972 | Bosma et al. | Sep 2002 | B1 |
6447531 | Amplatz | Sep 2002 | B1 |
6451050 | Rudakov et al. | Sep 2002 | B1 |
6454780 | Wallace | Sep 2002 | B1 |
6494884 | Gifford, Iii et al. | Dec 2002 | B2 |
6506204 | Mazzocchi | Jan 2003 | B2 |
6511468 | Cragg et al. | Jan 2003 | B1 |
6530934 | Jacobsen et al. | Mar 2003 | B1 |
6544278 | Vrba et al. | Apr 2003 | B1 |
6547804 | Porter et al. | Apr 2003 | B2 |
6551303 | Van Tassel et al. | Apr 2003 | B1 |
6569179 | Teoh et al. | May 2003 | B2 |
6579302 | Duerig et al. | Jun 2003 | B2 |
6579303 | Amplatz | Jun 2003 | B2 |
6585748 | Jeffree | Jul 2003 | B1 |
6585756 | Strecker | Jul 2003 | B1 |
6589256 | Forber | Jul 2003 | B2 |
6589265 | Palmer et al. | Jul 2003 | B1 |
6591472 | Noone et al. | Jul 2003 | B1 |
6592605 | Lenker et al. | Jul 2003 | B2 |
6599308 | Amplatz | Jul 2003 | B2 |
6602261 | Greene, Jr. et al. | Aug 2003 | B2 |
6605101 | Schaefer et al. | Aug 2003 | B1 |
6605102 | Mazzocchi et al. | Aug 2003 | B1 |
6605111 | Bose et al. | Aug 2003 | B2 |
6607551 | Sullivan et al. | Aug 2003 | B1 |
6613074 | Mitelberg et al. | Sep 2003 | B1 |
6626939 | Burnside et al. | Sep 2003 | B1 |
6632241 | Hancock et al. | Oct 2003 | B1 |
6635068 | Dubrul et al. | Oct 2003 | B1 |
6635069 | Teoh et al. | Oct 2003 | B1 |
6652555 | Vantassel et al. | Nov 2003 | B1 |
6652556 | Vantassel et al. | Nov 2003 | B1 |
6666882 | Bose et al. | Dec 2003 | B1 |
6666883 | Seguin et al. | Dec 2003 | B1 |
6669717 | Marotta et al. | Dec 2003 | B2 |
6669721 | Bose et al. | Dec 2003 | B1 |
6676696 | Marotta et al. | Jan 2004 | B1 |
6682505 | Bates et al. | Jan 2004 | B2 |
6682546 | Amplatz | Jan 2004 | B2 |
6689150 | Vantassel et al. | Feb 2004 | B1 |
6689486 | Ho et al. | Feb 2004 | B2 |
6695876 | Marotta et al. | Feb 2004 | B1 |
6698877 | Urlaub et al. | Mar 2004 | B2 |
6699274 | Stinson | Mar 2004 | B2 |
6709465 | Mitchell et al. | Mar 2004 | B2 |
6712835 | Mazzocchi et al. | Mar 2004 | B2 |
6723112 | Ho et al. | Apr 2004 | B2 |
6723116 | Taheri | Apr 2004 | B2 |
6730108 | Van Tassel et al. | May 2004 | B2 |
6746468 | Sepetka et al. | Jun 2004 | B1 |
6746890 | Gupta et al. | Jun 2004 | B2 |
6780196 | Chin et al. | Aug 2004 | B2 |
6792979 | Konya et al. | Sep 2004 | B2 |
6797083 | Peterson | Sep 2004 | B2 |
6802851 | Jones et al. | Oct 2004 | B2 |
RE38653 | Igaki et al. | Nov 2004 | E |
6811560 | Jones et al. | Nov 2004 | B2 |
6855153 | Saadat | Feb 2005 | B2 |
6855154 | Abdel-Gawwad | Feb 2005 | B2 |
RE38711 | Igaki et al. | Mar 2005 | E |
6860893 | Wallace et al. | Mar 2005 | B2 |
6878384 | Cruise et al. | Apr 2005 | B2 |
6905503 | Gifford, Iii et al. | Jun 2005 | B2 |
6936055 | Ken et al. | Aug 2005 | B1 |
6949103 | Mazzocchi et al. | Sep 2005 | B2 |
6949113 | Van Tassel et al. | Sep 2005 | B2 |
6953472 | Palmer et al. | Oct 2005 | B2 |
6979341 | Scribner et al. | Dec 2005 | B2 |
6989019 | Mazzocchi et al. | Jan 2006 | B2 |
6991617 | Hektner et al. | Jan 2006 | B2 |
6994092 | Van Der Burg et al. | Feb 2006 | B2 |
6994717 | Konya et al. | Feb 2006 | B2 |
7011671 | Welch | Mar 2006 | B2 |
7014645 | Greene, Jr. et al. | Mar 2006 | B2 |
7018401 | Hyodoh et al. | Mar 2006 | B1 |
7029487 | Greene, Jr. et al. | Apr 2006 | B2 |
7029949 | Farnworth et al. | Apr 2006 | B2 |
7033375 | Mazzocchi et al. | Apr 2006 | B2 |
7048752 | Mazzocchi et al. | May 2006 | B2 |
7063679 | Maguire et al. | Jun 2006 | B2 |
7070607 | Murayama et al. | Jul 2006 | B2 |
7070609 | West | Jul 2006 | B2 |
7083632 | Avellanet et al. | Aug 2006 | B2 |
7128073 | Van Der Burg et al. | Oct 2006 | B1 |
7128736 | Abrams et al. | Oct 2006 | B1 |
7153323 | Teoh et al. | Dec 2006 | B1 |
7169177 | Obara | Jan 2007 | B2 |
7195636 | Avellanet et al. | Mar 2007 | B2 |
7211109 | Thompson | May 2007 | B2 |
7229461 | Chin et al. | Jun 2007 | B2 |
7232461 | Ramer | Jun 2007 | B2 |
7244267 | Huter et al. | Jul 2007 | B2 |
7261720 | Stevens et al. | Aug 2007 | B2 |
7303571 | Makower et al. | Dec 2007 | B2 |
7306622 | Jones et al. | Dec 2007 | B2 |
7326225 | Ferrera et al. | Feb 2008 | B2 |
7331980 | Dubrul et al. | Feb 2008 | B2 |
7367985 | Mazzocchi et al. | May 2008 | B2 |
7367986 | Mazzocchi et al. | May 2008 | B2 |
7371250 | Mazzocchi et al. | May 2008 | B2 |
7393358 | Malewicz | Jul 2008 | B2 |
7404820 | Mazzocchi et al. | Jul 2008 | B2 |
7410482 | Murphy et al. | Aug 2008 | B2 |
7410492 | Mazzocchi et al. | Aug 2008 | B2 |
7413622 | Peterson | Aug 2008 | B2 |
7419503 | Pulnev et al. | Sep 2008 | B2 |
7442200 | Mazzocchi et al. | Oct 2008 | B2 |
7481821 | Fogarty et al. | Jan 2009 | B2 |
7485088 | Murphy et al. | Feb 2009 | B2 |
7491214 | Greene, Jr. et al. | Feb 2009 | B2 |
7556635 | Mazzocchi et al. | Jul 2009 | B2 |
7566338 | Mazzocchi et al. | Jul 2009 | B2 |
7569066 | Gerberding et al. | Aug 2009 | B2 |
7572273 | Mazzocchi et al. | Aug 2009 | B2 |
7572288 | Cox | Aug 2009 | B2 |
7575590 | Watson | Aug 2009 | B2 |
7597704 | Frazier et al. | Oct 2009 | B2 |
7601160 | Richter | Oct 2009 | B2 |
7608088 | Jones et al. | Oct 2009 | B2 |
7621928 | Thramann et al. | Nov 2009 | B2 |
7632296 | Malewicz | Dec 2009 | B2 |
7670355 | Mazzocchi et al. | Mar 2010 | B2 |
7670356 | Mazzocchi et al. | Mar 2010 | B2 |
7678130 | Mazzocchi et al. | Mar 2010 | B2 |
7682390 | Seguin | Mar 2010 | B2 |
7691124 | Balgobin | Apr 2010 | B2 |
7695488 | Berenstein et al. | Apr 2010 | B2 |
7699056 | Tran et al. | Apr 2010 | B2 |
7708754 | Balgobin et al. | May 2010 | B2 |
7727189 | Vantassel et al. | Jun 2010 | B2 |
7744583 | Seifert et al. | Jun 2010 | B2 |
7744652 | Morsi | Jun 2010 | B2 |
7763011 | Ortiz et al. | Jul 2010 | B2 |
7828815 | Mazzocchi et al. | Nov 2010 | B2 |
7828816 | Mazzocchi et al. | Nov 2010 | B2 |
7922732 | Mazzocchi et al. | Apr 2011 | B2 |
7955343 | Makower et al. | Jun 2011 | B2 |
7972359 | Kreidler | Jul 2011 | B2 |
7976527 | Cragg et al. | Jul 2011 | B2 |
RE42625 | Guglielmi | Aug 2011 | E |
7993364 | Morsi | Aug 2011 | B2 |
RE42758 | Ken et al. | Sep 2011 | E |
8012210 | Lin et al. | Sep 2011 | B2 |
8016869 | Nikolchev | Sep 2011 | B2 |
8016872 | Parker | Sep 2011 | B2 |
8043326 | Hancock et al. | Oct 2011 | B2 |
8062379 | Morsi | Nov 2011 | B2 |
8075585 | Lee et al. | Dec 2011 | B2 |
8137293 | Zhou et al. | Mar 2012 | B2 |
8142454 | Rosqueta et al. | Mar 2012 | B2 |
8202280 | Richter | Jun 2012 | B2 |
8211160 | Garrison et al. | Jul 2012 | B2 |
8221445 | Van Tassel et al. | Jul 2012 | B2 |
8261648 | Marchand et al. | Sep 2012 | B1 |
8298257 | Sepetka et al. | Oct 2012 | B2 |
8333783 | Braun et al. | Dec 2012 | B2 |
8343167 | Henson | Jan 2013 | B2 |
8361104 | Jones et al. | Jan 2013 | B2 |
8361138 | Adams | Jan 2013 | B2 |
8398670 | Amplatz et al. | Mar 2013 | B2 |
8425541 | Masters et al. | Apr 2013 | B2 |
8430012 | Marchand et al. | Apr 2013 | B1 |
8454681 | Holman et al. | Jun 2013 | B2 |
8470013 | Duggal et al. | Jun 2013 | B2 |
8597320 | Sepetka et al. | Dec 2013 | B2 |
8603128 | Greene, Jr. et al. | Dec 2013 | B2 |
8715317 | Janardhan et al. | May 2014 | B1 |
8834515 | Win et al. | Sep 2014 | B2 |
8906057 | Connor et al. | Dec 2014 | B2 |
8974512 | Aboytes et al. | Mar 2015 | B2 |
8998947 | Aboytes et al. | Apr 2015 | B2 |
9211202 | Strother et al. | Dec 2015 | B2 |
9301769 | Brady et al. | Apr 2016 | B2 |
9314248 | Molaei | Apr 2016 | B2 |
9486224 | Riina et al. | Nov 2016 | B2 |
9629636 | Fogarty et al. | Apr 2017 | B2 |
9833309 | Levi et al. | Dec 2017 | B2 |
9844380 | Furey | Dec 2017 | B2 |
9907684 | Connor et al. | Mar 2018 | B2 |
9962146 | Hebert et al. | May 2018 | B2 |
10028745 | Morsi | Jul 2018 | B2 |
20010000797 | Mazzocchi | May 2001 | A1 |
20010001835 | Greene et al. | May 2001 | A1 |
20010007082 | Dusbabek et al. | Jul 2001 | A1 |
20010012949 | Forber | Aug 2001 | A1 |
20010051822 | Stack et al. | Dec 2001 | A1 |
20020013599 | Limon et al. | Jan 2002 | A1 |
20020013618 | Marotta et al. | Jan 2002 | A1 |
20020026210 | Abdel-gawwad | Feb 2002 | A1 |
20020042628 | Chin et al. | Apr 2002 | A1 |
20020062091 | Jacobsen et al. | May 2002 | A1 |
20020062145 | Rudakov et al. | May 2002 | A1 |
20020111647 | Khairkhahan et al. | Aug 2002 | A1 |
20020119177 | Bowman et al. | Aug 2002 | A1 |
20020147462 | Mair et al. | Oct 2002 | A1 |
20020165572 | Saadat | Nov 2002 | A1 |
20020169473 | Sepetka et al. | Nov 2002 | A1 |
20020193812 | Patel et al. | Dec 2002 | A1 |
20020193813 | Helkowski et al. | Dec 2002 | A1 |
20030004533 | Dieck et al. | Jan 2003 | A1 |
20030004538 | Secrest et al. | Jan 2003 | A1 |
20030004568 | Ken et al. | Jan 2003 | A1 |
20030018294 | Cox | Jan 2003 | A1 |
20030028209 | Teoh et al. | Feb 2003 | A1 |
20030040772 | Hyodoh et al. | Feb 2003 | A1 |
20030055440 | Jones et al. | Mar 2003 | A1 |
20030057156 | Peterson et al. | Mar 2003 | A1 |
20030093111 | Ken et al. | May 2003 | A1 |
20030113478 | Dang et al. | Jun 2003 | A1 |
20030114918 | Garrison et al. | Jun 2003 | A1 |
20030149490 | Ashman | Aug 2003 | A1 |
20030171739 | Murphy et al. | Sep 2003 | A1 |
20030171770 | Kusleika et al. | Sep 2003 | A1 |
20030176884 | Berrada et al. | Sep 2003 | A1 |
20030187473 | Berenstein et al. | Oct 2003 | A1 |
20030195553 | Wallace | Oct 2003 | A1 |
20030199913 | Dubrul et al. | Oct 2003 | A1 |
20030199919 | Palmer et al. | Oct 2003 | A1 |
20030212419 | West | Nov 2003 | A1 |
20040015224 | Armstrong et al. | Jan 2004 | A1 |
20040034386 | Fulton et al. | Feb 2004 | A1 |
20040044361 | Frazier et al. | Mar 2004 | A1 |
20040044391 | Porter | Mar 2004 | A1 |
20040064093 | Hektner et al. | Apr 2004 | A1 |
20040098027 | Teoh et al. | May 2004 | A1 |
20040098030 | Makower et al. | May 2004 | A1 |
20040106945 | Thramann et al. | Jun 2004 | A1 |
20040106977 | Sullivan et al. | Jun 2004 | A1 |
20040111112 | Hoffmann | Jun 2004 | A1 |
20040115164 | Pierce et al. | Jun 2004 | A1 |
20040122467 | Vantassel et al. | Jun 2004 | A1 |
20040122468 | Yodfat et al. | Jun 2004 | A1 |
20040138758 | Kronengold et al. | Jul 2004 | A1 |
20040143239 | Zhou et al. | Jul 2004 | A1 |
20040143286 | Johnson et al. | Jul 2004 | A1 |
20040153119 | Kusleika et al. | Aug 2004 | A1 |
20040161451 | Pierce et al. | Aug 2004 | A1 |
20040162606 | Thompson | Aug 2004 | A1 |
20040172056 | Guterman | Sep 2004 | A1 |
20040172121 | Eidenschink et al. | Sep 2004 | A1 |
20040181253 | Sepetka et al. | Sep 2004 | A1 |
20040186562 | Cox | Sep 2004 | A1 |
20040193206 | Gerberding et al. | Sep 2004 | A1 |
20040215229 | Coyle | Oct 2004 | A1 |
20040215332 | Frid | Oct 2004 | A1 |
20040249408 | Murphy et al. | Dec 2004 | A1 |
20040267346 | Shelso | Dec 2004 | A1 |
20050010281 | Yodfat et al. | Jan 2005 | A1 |
20050021077 | Chin et al. | Jan 2005 | A1 |
20050033408 | Jones et al. | Feb 2005 | A1 |
20050033409 | Burke et al. | Feb 2005 | A1 |
20050049625 | Shaya et al. | Mar 2005 | A1 |
20050060017 | Fischell et al. | Mar 2005 | A1 |
20050096728 | Ramer | May 2005 | A1 |
20050096732 | Marotta et al. | May 2005 | A1 |
20050107823 | Leone et al. | May 2005 | A1 |
20050131443 | Abdel-Gawwad | Jun 2005 | A1 |
20050222580 | Gifford et al. | Oct 2005 | A1 |
20050222605 | Greenhalgh et al. | Oct 2005 | A1 |
20050228434 | Amplatz | Oct 2005 | A1 |
20050267510 | Razack | Dec 2005 | A1 |
20050267511 | Marks et al. | Dec 2005 | A1 |
20050267527 | Sandoval et al. | Dec 2005 | A1 |
20050267568 | Berez et al. | Dec 2005 | A1 |
20050273135 | Chanduszko et al. | Dec 2005 | A1 |
20050277978 | Greenhalgh | Dec 2005 | A1 |
20050278023 | Zwirkoski | Dec 2005 | A1 |
20050288763 | Andreas et al. | Dec 2005 | A1 |
20060034883 | Dang et al. | Feb 2006 | A1 |
20060052816 | Bates et al. | Mar 2006 | A1 |
20060064151 | Guterman et al. | Mar 2006 | A1 |
20060074475 | Gumm | Apr 2006 | A1 |
20060106421 | Teoh | May 2006 | A1 |
20060116709 | Sepetka et al. | Jun 2006 | A1 |
20060116712 | Sepetka et al. | Jun 2006 | A1 |
20060116713 | Sepetka et al. | Jun 2006 | A1 |
20060116714 | Sepetka et al. | Jun 2006 | A1 |
20060122548 | Abrams | Jun 2006 | A1 |
20060155323 | Porter et al. | Jul 2006 | A1 |
20060167494 | Suddaby | Jul 2006 | A1 |
20060190070 | Dieck et al. | Aug 2006 | A1 |
20060190076 | Taheri | Aug 2006 | A1 |
20060200221 | Malewicz | Sep 2006 | A1 |
20060200234 | Hines | Sep 2006 | A1 |
20060206140 | Shaolian et al. | Sep 2006 | A1 |
20060206198 | Churchwell et al. | Sep 2006 | A1 |
20060206199 | Churchwell et al. | Sep 2006 | A1 |
20060206200 | Garcia et al. | Sep 2006 | A1 |
20060217799 | Mailänder et al. | Sep 2006 | A1 |
20060224183 | Freudenthal | Oct 2006 | A1 |
20060229700 | Acosta et al. | Oct 2006 | A1 |
20060235464 | Avellanet et al. | Oct 2006 | A1 |
20060235501 | Igaki | Oct 2006 | A1 |
20060241686 | Ferrera et al. | Oct 2006 | A1 |
20060241690 | Amplatz et al. | Oct 2006 | A1 |
20060247680 | Amplatz | Nov 2006 | A1 |
20060264905 | Eskridge et al. | Nov 2006 | A1 |
20060264907 | Eskridge et al. | Nov 2006 | A1 |
20060271149 | Berez et al. | Nov 2006 | A1 |
20060271153 | Garcia et al. | Nov 2006 | A1 |
20060271162 | Vito et al. | Nov 2006 | A1 |
20060282152 | Beyerlein et al. | Dec 2006 | A1 |
20060292206 | Kim et al. | Dec 2006 | A1 |
20060293744 | Peckham et al. | Dec 2006 | A1 |
20070003594 | Brady et al. | Jan 2007 | A1 |
20070005125 | Berenstein et al. | Jan 2007 | A1 |
20070010850 | Balgobin et al. | Jan 2007 | A1 |
20070014831 | Sung et al. | Jan 2007 | A1 |
20070016243 | Ramaiah et al. | Jan 2007 | A1 |
20070021816 | Rudin | Jan 2007 | A1 |
20070050017 | Sims et al. | Mar 2007 | A1 |
20070083226 | Buiser et al. | Apr 2007 | A1 |
20070088387 | Eskridge et al. | Apr 2007 | A1 |
20070093889 | Wu et al. | Apr 2007 | A1 |
20070100415 | Licata et al. | May 2007 | A1 |
20070100426 | Rudakov et al. | May 2007 | A1 |
20070106311 | Wallace et al. | May 2007 | A1 |
20070135826 | Zaver et al. | Jun 2007 | A1 |
20070135907 | Wilson et al. | Jun 2007 | A1 |
20070150045 | Ferrera | Jun 2007 | A1 |
20070162104 | Frid | Jul 2007 | A1 |
20070167876 | Euteneuer et al. | Jul 2007 | A1 |
20070167877 | Euteneuer et al. | Jul 2007 | A1 |
20070167972 | Euteneuer et al. | Jul 2007 | A1 |
20070167980 | Figulla et al. | Jul 2007 | A1 |
20070173928 | Morsi | Jul 2007 | A1 |
20070175536 | Monetti et al. | Aug 2007 | A1 |
20070179520 | West | Aug 2007 | A1 |
20070185442 | Euteneuer et al. | Aug 2007 | A1 |
20070185443 | Euteneuer et al. | Aug 2007 | A1 |
20070185444 | Euteneuer et al. | Aug 2007 | A1 |
20070185457 | Euteneuer et al. | Aug 2007 | A1 |
20070191884 | Eskridge et al. | Aug 2007 | A1 |
20070191924 | Rudakov | Aug 2007 | A1 |
20070198059 | Patel et al. | Aug 2007 | A1 |
20070198075 | Levy | Aug 2007 | A1 |
20070203567 | Levy | Aug 2007 | A1 |
20070219619 | Dieck et al. | Sep 2007 | A1 |
20070221230 | Thompson et al. | Sep 2007 | A1 |
20070225760 | Moszner et al. | Sep 2007 | A1 |
20070225794 | Thramann et al. | Sep 2007 | A1 |
20070233224 | Leynov et al. | Oct 2007 | A1 |
20070233244 | Lopez et al. | Oct 2007 | A1 |
20070239261 | Bose et al. | Oct 2007 | A1 |
20070265656 | Amplatz et al. | Nov 2007 | A1 |
20070270902 | Slazas et al. | Nov 2007 | A1 |
20070276426 | Euteneuer | Nov 2007 | A1 |
20070276427 | Euteneuer | Nov 2007 | A1 |
20070282373 | Ashby et al. | Dec 2007 | A1 |
20070288083 | Hines | Dec 2007 | A1 |
20070293935 | Olsen et al. | Dec 2007 | A1 |
20080009934 | Schneider et al. | Jan 2008 | A1 |
20080021535 | Leopold et al. | Jan 2008 | A1 |
20080033366 | Matson et al. | Feb 2008 | A1 |
20080039933 | Yodfat et al. | Feb 2008 | A1 |
20080045996 | Makower et al. | Feb 2008 | A1 |
20080045997 | Balgobin et al. | Feb 2008 | A1 |
20080051705 | Von Oepen et al. | Feb 2008 | A1 |
20080058856 | Ramaiah et al. | Mar 2008 | A1 |
20080065141 | Holman et al. | Mar 2008 | A1 |
20080065145 | Carpenter | Mar 2008 | A1 |
20080081763 | Swetlin et al. | Apr 2008 | A1 |
20080082176 | Slazas | Apr 2008 | A1 |
20080086196 | Truckai et al. | Apr 2008 | A1 |
20080097495 | Feller et al. | Apr 2008 | A1 |
20080109057 | Calabria et al. | May 2008 | A1 |
20080109063 | Hancock et al. | May 2008 | A1 |
20080114391 | Dieck et al. | May 2008 | A1 |
20080114436 | Dieck et al. | May 2008 | A1 |
20080114439 | Ramaiah et al. | May 2008 | A1 |
20080119886 | Greenhalgh et al. | May 2008 | A1 |
20080125806 | Mazzocchi et al. | May 2008 | A1 |
20080125848 | Kusleika et al. | May 2008 | A1 |
20080125852 | Garrison et al. | May 2008 | A1 |
20080132820 | Buckman et al. | Jun 2008 | A1 |
20080132989 | Snow et al. | Jun 2008 | A1 |
20080140177 | Hines | Jun 2008 | A1 |
20080154286 | Abbott et al. | Jun 2008 | A1 |
20080195139 | Donald et al. | Aug 2008 | A1 |
20080200945 | Amplatz et al. | Aug 2008 | A1 |
20080200979 | Dieck et al. | Aug 2008 | A1 |
20080219533 | Grigorescu | Sep 2008 | A1 |
20080221600 | Dieck et al. | Sep 2008 | A1 |
20080243226 | Fernandez et al. | Oct 2008 | A1 |
20080249562 | Cahill | Oct 2008 | A1 |
20080255603 | Naor et al. | Oct 2008 | A1 |
20080262598 | Elmaleh | Oct 2008 | A1 |
20080281350 | Sepetka et al. | Nov 2008 | A1 |
20080319533 | Lehe | Dec 2008 | A1 |
20090018637 | Paul, Jr. et al. | Jan 2009 | A1 |
20090024224 | Chen et al. | Jan 2009 | A1 |
20090025820 | Adams | Jan 2009 | A1 |
20090043375 | Rudakov et al. | Feb 2009 | A1 |
20090056722 | Swann | Mar 2009 | A1 |
20090062899 | Dang et al. | Mar 2009 | A1 |
20090069806 | De La Mora et al. | Mar 2009 | A1 |
20090076540 | Marks et al. | Mar 2009 | A1 |
20090082803 | Adams | Mar 2009 | A1 |
20090099647 | Glimsdale et al. | Apr 2009 | A1 |
20090112249 | Miles et al. | Apr 2009 | A1 |
20090112251 | Qian et al. | Apr 2009 | A1 |
20090118811 | Moloney | May 2009 | A1 |
20090125094 | Rust | May 2009 | A1 |
20090125119 | Obermiller et al. | May 2009 | A1 |
20090143849 | Ozawa et al. | Jun 2009 | A1 |
20090143851 | Paul, Jr. | Jun 2009 | A1 |
20090148492 | Dave et al. | Jun 2009 | A1 |
20090155367 | Neuwirth et al. | Jun 2009 | A1 |
20090187214 | Amplatz et al. | Jul 2009 | A1 |
20090192587 | Frid | Jul 2009 | A1 |
20090198315 | Boudjemline | Aug 2009 | A1 |
20090204145 | Matthews | Aug 2009 | A1 |
20090210047 | Amplatz et al. | Aug 2009 | A1 |
20090216307 | Kaufmann et al. | Aug 2009 | A1 |
20090228029 | Lee | Sep 2009 | A1 |
20090228093 | Taylor et al. | Sep 2009 | A1 |
20090259202 | Leeflang et al. | Oct 2009 | A1 |
20090264914 | Riina et al. | Oct 2009 | A1 |
20090264978 | Dieck et al. | Oct 2009 | A1 |
20090275974 | Marchand et al. | Nov 2009 | A1 |
20090287291 | Becking et al. | Nov 2009 | A1 |
20090287292 | Becking et al. | Nov 2009 | A1 |
20090287294 | Rosqueta et al. | Nov 2009 | A1 |
20090287297 | Cox | Nov 2009 | A1 |
20090297582 | Meyer et al. | Dec 2009 | A1 |
20090306702 | Miloslavski et al. | Dec 2009 | A1 |
20090318892 | Aboytes et al. | Dec 2009 | A1 |
20090318941 | Sepetka et al. | Dec 2009 | A1 |
20090318948 | Davis et al. | Dec 2009 | A1 |
20090319023 | Hildebrand et al. | Dec 2009 | A1 |
20100004726 | Hancock et al. | Jan 2010 | A1 |
20100004761 | Flanders et al. | Jan 2010 | A1 |
20100023048 | Mach | Jan 2010 | A1 |
20100023105 | Levy et al. | Jan 2010 | A1 |
20100030200 | Strauss et al. | Feb 2010 | A1 |
20100030220 | Truckai et al. | Feb 2010 | A1 |
20100036390 | Gumm | Feb 2010 | A1 |
20100036410 | Krolik et al. | Feb 2010 | A1 |
20100042133 | Ramzipoor et al. | Feb 2010 | A1 |
20100069948 | Veznedaroglu et al. | Mar 2010 | A1 |
20100087908 | Hilaire et al. | Apr 2010 | A1 |
20100094335 | Gerberding et al. | Apr 2010 | A1 |
20100106178 | Obermiller et al. | Apr 2010 | A1 |
20100131002 | Connor et al. | May 2010 | A1 |
20100139465 | Christian et al. | Jun 2010 | A1 |
20100144895 | Porter | Jun 2010 | A1 |
20100152767 | Greenhalgh et al. | Jun 2010 | A1 |
20100174269 | Tompkins et al. | Jul 2010 | A1 |
20100185271 | Zhang | Jul 2010 | A1 |
20100222802 | Gillespie, Jr. et al. | Sep 2010 | A1 |
20100228184 | Mavani et al. | Sep 2010 | A1 |
20100249830 | Nelson | Sep 2010 | A1 |
20100249894 | Oba et al. | Sep 2010 | A1 |
20100256527 | Lippert et al. | Oct 2010 | A1 |
20100256528 | Lippert et al. | Oct 2010 | A1 |
20100256601 | Lippert et al. | Oct 2010 | A1 |
20100256602 | Lippert et al. | Oct 2010 | A1 |
20100256603 | Lippert et al. | Oct 2010 | A1 |
20100256604 | Lippert et al. | Oct 2010 | A1 |
20100256605 | Lippert et al. | Oct 2010 | A1 |
20100256606 | Lippert et al. | Oct 2010 | A1 |
20100262014 | Huang | Oct 2010 | A1 |
20100268201 | Tieu et al. | Oct 2010 | A1 |
20100268260 | Riina et al. | Oct 2010 | A1 |
20100274276 | Chow et al. | Oct 2010 | A1 |
20100298791 | Jones et al. | Nov 2010 | A1 |
20100312061 | Hess et al. | Dec 2010 | A1 |
20100312270 | Mcguckin, Jr. et al. | Dec 2010 | A1 |
20100331948 | Turovskiy et al. | Dec 2010 | A1 |
20110022149 | Cox et al. | Jan 2011 | A1 |
20110046658 | Connor et al. | Feb 2011 | A1 |
20110054519 | Neuss | Mar 2011 | A1 |
20110077620 | Debeer | Mar 2011 | A1 |
20110082493 | Samson et al. | Apr 2011 | A1 |
20110106234 | Grandt | May 2011 | A1 |
20110125110 | Cotton | May 2011 | A1 |
20110137332 | Sepetka et al. | Jun 2011 | A1 |
20110137405 | Wilson et al. | Jun 2011 | A1 |
20110144669 | Becking et al. | Jun 2011 | A1 |
20110152993 | Marchand et al. | Jun 2011 | A1 |
20110166588 | Connor et al. | Jul 2011 | A1 |
20110184452 | Huynh et al. | Jul 2011 | A1 |
20110184453 | Levy et al. | Jul 2011 | A1 |
20110196415 | Ujiie et al. | Aug 2011 | A1 |
20110202085 | Loganathan et al. | Aug 2011 | A1 |
20110208227 | Becking | Aug 2011 | A1 |
20110224776 | Sepetka et al. | Sep 2011 | A1 |
20110245862 | Dieck et al. | Oct 2011 | A1 |
20110251699 | Ladet | Oct 2011 | A1 |
20110265943 | Rosqueta et al. | Nov 2011 | A1 |
20110276120 | Gilson et al. | Nov 2011 | A1 |
20110313447 | Strauss et al. | Dec 2011 | A1 |
20110319926 | Becking et al. | Dec 2011 | A1 |
20120010644 | Sideris et al. | Jan 2012 | A1 |
20120022572 | Braun et al. | Jan 2012 | A1 |
20120041470 | Shrivastava et al. | Feb 2012 | A1 |
20120041472 | Tan et al. | Feb 2012 | A1 |
20120065720 | Strauss et al. | Mar 2012 | A1 |
20120101510 | Lenker et al. | Apr 2012 | A1 |
20120101561 | Porter | Apr 2012 | A1 |
20120116350 | Strauss et al. | May 2012 | A1 |
20120143237 | Cam et al. | Jun 2012 | A1 |
20120143243 | Hill et al. | Jun 2012 | A1 |
20120143317 | Cam et al. | Jun 2012 | A1 |
20120165803 | Bencini et al. | Jun 2012 | A1 |
20120165919 | Cox et al. | Jun 2012 | A1 |
20120197283 | Marchand et al. | Aug 2012 | A1 |
20120226343 | Vo et al. | Sep 2012 | A1 |
20120239074 | Aboytes et al. | Sep 2012 | A1 |
20120245674 | Molaei et al. | Sep 2012 | A1 |
20120245675 | Molaei et al. | Sep 2012 | A1 |
20120283768 | Cox et al. | Nov 2012 | A1 |
20120283769 | Cruise et al. | Nov 2012 | A1 |
20120310269 | Fearnot et al. | Dec 2012 | A1 |
20120316598 | Becking et al. | Dec 2012 | A1 |
20120316632 | Gao | Dec 2012 | A1 |
20120323271 | Obermiller et al. | Dec 2012 | A1 |
20120330341 | Becking et al. | Dec 2012 | A1 |
20120330347 | Becking et al. | Dec 2012 | A1 |
20120330348 | Strauss et al. | Dec 2012 | A1 |
20130018451 | Grabowski et al. | Jan 2013 | A1 |
20130066357 | Aboytes et al. | Mar 2013 | A1 |
20130066360 | Becking et al. | Mar 2013 | A1 |
20130085522 | Becking et al. | Apr 2013 | A1 |
20130092013 | Thompson et al. | Apr 2013 | A1 |
20130116722 | Aboytes et al. | May 2013 | A1 |
20130123830 | Becking et al. | May 2013 | A1 |
20130211495 | Halden et al. | Aug 2013 | A1 |
20130233160 | Marchand et al. | Sep 2013 | A1 |
20130239790 | Thompson et al. | Sep 2013 | A1 |
20130245667 | Marchand et al. | Sep 2013 | A1 |
20130245670 | Fan | Sep 2013 | A1 |
20130268053 | Molaei et al. | Oct 2013 | A1 |
20130274862 | Cox et al. | Oct 2013 | A1 |
20130274863 | Cox et al. | Oct 2013 | A1 |
20130274866 | Cox et al. | Oct 2013 | A1 |
20130274868 | Cox et al. | Oct 2013 | A1 |
20130304179 | Bialas et al. | Nov 2013 | A1 |
20130345739 | Brady et al. | Dec 2013 | A1 |
20140005713 | Bowman | Jan 2014 | A1 |
20140012307 | Franano et al. | Jan 2014 | A1 |
20140058420 | Hannes et al. | Feb 2014 | A1 |
20140135810 | Divino et al. | May 2014 | A1 |
20140135811 | Divino et al. | May 2014 | A1 |
20140135812 | Divino et al. | May 2014 | A1 |
20140316012 | Freyman et al. | Oct 2014 | A1 |
20140371734 | Truckai | Dec 2014 | A1 |
20150216684 | Enzmann et al. | Aug 2015 | A1 |
20150250628 | Monstadt et al. | Sep 2015 | A1 |
20150272590 | Aboytes et al. | Oct 2015 | A1 |
20150313737 | Tippett et al. | Nov 2015 | A1 |
20150327843 | Garrison | Nov 2015 | A1 |
20150342613 | Aboytes et al. | Dec 2015 | A1 |
20160022445 | Ruvalcaba et al. | Jan 2016 | A1 |
20160030050 | Franano et al. | Feb 2016 | A1 |
20160066921 | Seifert et al. | Mar 2016 | A1 |
20160135984 | Rudakov et al. | May 2016 | A1 |
20160206320 | Connor | Jul 2016 | A1 |
20160206321 | Connor | Jul 2016 | A1 |
20170150971 | Hines | Jun 2017 | A1 |
20170156903 | Shobayashi | Jun 2017 | A1 |
20170189035 | Porter | Jul 2017 | A1 |
20170266023 | Thomas | Sep 2017 | A1 |
20170340333 | Badruddin et al. | Nov 2017 | A1 |
20170367708 | Mayer et al. | Dec 2017 | A1 |
20180049859 | Stoppenhagen et al. | Feb 2018 | A1 |
20180125686 | Lu | May 2018 | A1 |
20180140305 | Connor | May 2018 | A1 |
20180161185 | Kresslein et al. | Jun 2018 | A1 |
20180193025 | Walzman | Jul 2018 | A1 |
20180193026 | Yang et al. | Jul 2018 | A1 |
20180206852 | Moeller | Jul 2018 | A1 |
20190053811 | Garza et al. | Feb 2019 | A1 |
20190282242 | Divino et al. | Sep 2019 | A1 |
20190343532 | Divino et al. | Nov 2019 | A1 |
20200061099 | Li et al. | Feb 2020 | A1 |
20200367904 | Becking et al. | Nov 2020 | A1 |
Number | Date | Country |
---|---|---|
2607529 | Apr 2008 | CA |
101472537 | Jul 2009 | CN |
102083493 | Jun 2011 | CN |
1283434 | Nov 1968 | DE |
102008028308 | Apr 2009 | DE |
102010050569 | May 2012 | DE |
102011011510 | Aug 2012 | DE |
102011102933 | Dec 2012 | DE |
0717969 | Jun 1996 | EP |
0743047 | Nov 1996 | EP |
0855170 | Jul 1998 | EP |
0775470 | Mar 1999 | EP |
1188414 | Mar 2002 | EP |
1621148 | Feb 2006 | EP |
1637176 | Mar 2006 | EP |
1752112 | Feb 2007 | EP |
1813213 | Aug 2007 | EP |
1923019 | May 2008 | EP |
1942972 | Jul 2008 | EP |
1872742 | May 2009 | EP |
2208483 | Jul 2010 | EP |
2279023 | Feb 2011 | EP |
2363075 | Sep 2011 | EP |
2496299 | Sep 2012 | EP |
2675402 | Dec 2013 | EP |
2556210 | Apr 1988 | FR |
2890306 | Mar 2007 | FR |
11506686 | Jun 1999 | JP |
2003520103 | Jul 2003 | JP |
2003524434 | Aug 2003 | JP |
2004049585 | Feb 2004 | JP |
2005522266 | Jul 2005 | JP |
2005261951 | Sep 2005 | JP |
2006506201 | Feb 2006 | JP |
2008521492 | Jun 2008 | JP |
2008541832 | Nov 2008 | JP |
4673987 | Jan 2011 | JP |
WO 8800813 | Feb 1988 | WO |
WO 9406502 | Mar 1994 | WO |
WO 9601591 | Jan 1996 | WO |
WO 9726939 | Jul 1997 | WO |
WO 9903404 | Jan 1999 | WO |
WO 9905977 | Feb 1999 | WO |
WO 9908607 | Feb 1999 | WO |
WO 9908743 | Feb 1999 | WO |
WO 9940873 | Aug 1999 | WO |
WO 9962432 | Dec 1999 | WO |
WO 0057815 | Oct 2000 | WO |
WO 0193782 | Dec 2001 | WO |
WO 0200139 | Jan 2002 | WO |
WO 02071977 | Sep 2002 | WO |
WO 03011151 | Feb 2003 | WO |
WO 03037191 | May 2003 | WO |
WO 2005117718 | Dec 2005 | WO |
WO 2006026744 | Mar 2006 | WO |
WO 2006034149 | Mar 2006 | WO |
WO 2006034166 | Mar 2006 | WO |
WO 2006052322 | May 2006 | WO |
WO 2006091891 | Aug 2006 | WO |
WO 2006119422 | Nov 2006 | WO |
WO 2007006139 | Jan 2007 | WO |
WO 2007047851 | Apr 2007 | WO |
WO 2007076480 | Jul 2007 | WO |
WO 2007095031 | Aug 2007 | WO |
WO 2007121405 | Oct 2007 | WO |
WO 2008022327 | Feb 2008 | WO |
WO 2008074027 | Jun 2008 | WO |
WO 2008109228 | Sep 2008 | WO |
WO 2008151204 | Dec 2008 | WO |
WO 2008157507 | Dec 2008 | WO |
WO 2009014528 | Jan 2009 | WO |
WO 2009076515 | Jun 2009 | WO |
WO 2009132045 | Oct 2009 | WO |
WO 2009134337 | Nov 2009 | WO |
WO 2009135166 | Nov 2009 | WO |
WO 2010009019 | Jan 2010 | WO |
WO 2010027363 | Mar 2010 | WO |
WO 2010028300 | Mar 2010 | WO |
WO 2010030991 | Mar 2010 | WO |
WO 2010077599 | Jul 2010 | WO |
WO 2010147808 | Dec 2010 | WO |
WO 2011057002 | May 2011 | WO |
WO 2011057277 | May 2011 | WO |
WO 2011066962 | Jun 2011 | WO |
WO 2011095966 | Aug 2011 | WO |
WO 2011130081 | Oct 2011 | WO |
WO 2011153304 | Dec 2011 | WO |
WO 2012034135 | Mar 2012 | WO |
WO 2012068175 | May 2012 | WO |
WO 2012112749 | Aug 2012 | WO |
WO 2012166804 | Dec 2012 | WO |
WO 2013112944 | Aug 2013 | WO |
WO 2013138615 | Sep 2013 | WO |
WO 2013138615 | Sep 2014 | WO |
WO 2017074411 | May 2017 | WO |
WO 2018051187 | Mar 2018 | WO |
Entry |
---|
Hill, et al., “Initial Results of the AMO LA TZER Vascular Plug in the Treatment of Congenital Heart Disease, Business Briefing,” US Cardiology 2004. |
Ronnen, “Amplatzer Vascular Plug Case Study, Closure of Arteriovenous Fistula Between Deep Femoral Artery and Superficial Femoral Vein,” AGA Medical Corporation, May 2007. |
Thorell, et al., “Y-configured Dual Intracranial Stent-assisted Coil Embolization for the Treatment of Wide-necked Basilar Tip Aneurysms”, Neurosurgery, May 2005, vol. 56, Issue 5, pp. 1035-1040. |
Number | Date | Country | |
---|---|---|---|
20220022886 A1 | Jan 2022 | US |
Number | Date | Country | |
---|---|---|---|
61145097 | Jan 2009 | US | |
61083961 | Jul 2008 | US | |
61083957 | Jul 2008 | US | |
61046670 | Apr 2008 | US | |
61046594 | Apr 2008 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16893431 | Jun 2020 | US |
Child | 17408329 | US | |
Parent | 15415669 | Jan 2017 | US |
Child | 16893431 | US | |
Parent | 13470013 | May 2012 | US |
Child | 15415669 | US | |
Parent | 12911034 | Oct 2010 | US |
Child | 13470013 | US | |
Parent | 12427620 | Apr 2009 | US |
Child | 12911034 | US |